Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2026 08:00 ET | Source: Mira Pharmaceuticals, Inc.

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

MIRA advances MIRA-55 and SKNY-1 through exploratory toxicology, CMC and manufacturing activities supporting future IND-enabling studies.
July 22, 2026 15:10 ET | Source: Serenity Medical

Serenity Medical’s River Stent™ Demonstrates Sustained 4- to 5-Year Benefits in Patients with Idiopathic Intracranial Hypertension (IIH), Presented at SNIS Annual Meeting in Late-Breaking Session

MAPLE GROVE, Minn., July 22, 2026 (GLOBE NEWSWIRE) -- Serenity Medical, a NeuroTechnology Investors (NTI) portfolio company and pioneer in venous sinus stenosis treatment, today announced during a...
July 16, 2026 01:00 ET | Source: Boehringer Ingelheim

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development

Not intended for UK and US audiencesBoehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701, in people...
July 15, 2026 11:51 ET | Source: Novo Nordisk A/S

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved

EU approves Novo Nordisk's Wegovy® pill as first oral GLP-1 for weight management; as well as ready-to-use pen for Wegovy 7.2 mg injection
July 15, 2026 04:15 ET | Source: Research and Markets

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Oral Obesity Therapies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Oral Obesity Therapies Market Global Report...
July 09, 2026 22:14 ET | Source: MindRank AI Ltd.

MindRank Announces $52 Million Series B Financing

Funding to advance AI-native drug R&D engine and pipelines, including MDR-001, an oral GLP-1 small-molecule in Phase III clinical trials in China.
July 07, 2026 07:35 ET | Source: Vivani Medical, Inc.

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical entered into agreement with Novo Nordisk to evaluate its miniature subdermal semaglutide (GLP-1) implant for weight management
July 07, 2026 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535
July 03, 2026 04:30 ET | Source: Custom Market Insights

[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 03, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Antidiabetic Drugs Market Size, Trends, and Insights By Drug Class (Insulin,...
July 01, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences